H. Lundbeck A/S held its Annual General Meeting on 21 April 2008 at the company's registered office
At the general meeting the report by the Supervisory Board and the Annual Report were approved, and the Supervisory Board and Executive Management were discharged from liability. The general meeting approved the dividend of DKK 2.30 per share of DKK 5 nominal value proposed by the Supervisory Board. Per Wold-Olsen, Thorleif Krarup, Peter Kürstein, Mats Pettersson, Jes Østergaard and Egil Bodd were all re-elected to the Supervisory Board. Immediately after the general meeting, the Supervisory Board elected Per Wold-Olsen Chairman and Thorleif Krarup Deputy Chairman of the Supervisory Board. After having elected its Chairman and Deputy Chairman, the Supervisory Board appointed members for the Audit Committee and the Remuneration Committee. Peter Kürstein, Egil Bodd and Thorleif Krarup were re-elected as members of the Audit Committee. Per Wold-Olsen, Jes Østergaard and Mats Pettersson were re-elected as members of the Remuneration Committee. The Supervisory Board of H. Lundbeck A/S will hereafter comprise: - Per Wold-Olsen - Thorleif Krarup - Peter Kürstein - Mats Pettersson - Jes Østergaard - Egil Bodd - Birgit Bundgaard Rosenmeier (employee representative) - Jens Møller Mayntzhusen (employee representative) - Kim Rosenville Christensen (employee representative) Deloitte Statsautoriseret Revisionsaktieselskab was re-appointed as the company's auditor. The Supervisory Board's proposed resolutions under item 6 of the agenda were adopted. Consequently, a resolution was adopted to reduce the share capital of the company by DKK 3,848,240 nominal value of the company's holding of treasury shares acquired from shareholders of the company as part of the implementation of share buyback programmes. The proposal was adopted to change the deadline for the Board's exercise of its authorisation under Article 4.1 from "until 30 March 2009" to "until 30 March 2014". A new Article 16.0 was inserted in the Articles of Association with a provision governing electronic communication and Article 7.1 was amended accordingly. Finally, the chairman of the general meeting was authorised to make such changes in and supplements to the resolutions adopted by the general meeting and the notification to the Danish Commerce and Companies Agency as may be requested by the Commerce and Companies Agency in connection with its registration of the amendments made. No other business was transacted at the general meeting. Supervisory Board The content of this release will have no influence on the Lundbeck Group's financial result for 2009. Lundbeck contacts Investors: Media: Jacob Tolstrup Mads Kronborg Director, IR & Communication Media Relations +45 36 43 30 79 +45 36 43 28 51 Palle Holm Olesen Head of Investor Relations +45 36 43 24 26 About Lundbeck H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). The number of employees is approx. 5,500 globally. For more information, please visit www.lundbeck.com.